GRAIL: A Major Trial Disappointment

Caffital Research1.95K FollowersFollow5ShareSavePlay(8min)CommentsSummaryGRAIL, Inc. reported topline results from the extensive NHS-Galleri trial. The trial didn't find statistically significant evidence of clinical utility in the main endpoint.The result is a clear disappointment and has major implications for GRAIL's commercialization of Galleri.GRAIL's financials performed largely as expected in Q4.The investment case for GRAIL is now more uncertain. ediebloom/iStock via Getty Images GRAIL, Inc. (GRAL) reported the extensive NHS-Galleri trial’s results alongside the company’s Q4 results. The trial results weren’t as good as was hoped; the stock has reacted very strongly due to the lack of statistically significantThis article was written byCaffital Research1.95K FollowersFollowI am an avid investor with a major focus on small cap companies with experience in investing in US, Canadian, and European markets. My investment philosophy to generating great returns on the stock market revolves around identifying mispriced securities by understanding the drivers behind a company's financials, and ultimately, most often revealed by a DCF model valuation. This methodology doesn't limit an investor into rigid traditional value, dividend, or growth investing, but rather accounts for all of a stock's prospects to determine the risk-to-reward.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.